Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.43 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | SGK1 | O00141 | 1/20 | 0.37 |
| ▸ | TPH1 | P17752 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL588938 | 0.92 | NEK2 (0.41) | KDRGPR68CCNT1CCNE1CDK2 | |
| SCHEMBL589262 | 0.78 | NEK2 (0.46) | KDRCCNT1CCNE1CDK2CDK9 | |
| Hydrochloric Acid SCHEMBL589256 | 0.77 | NEK2 (0.46) | KDRCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL10151169 | 0.75 | CCNT1 (0.49) | KDRCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL588761 | 0.71 | PKMYT1 (0.59) | KDRCDK2PKMYT1CSF1RRET | |
| SCHEMBL31672487 | 0.69 | KDR (0.46) | KDRCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL31672451 | 0.69 | KDR (0.62) | KDR | |
| SCHEMBL10151178 | 0.69 | KDR (0.62) | KDR | |
| SCHEMBL10151171 | 0.69 | KDR (0.46) | KDRCCNT1CCNE1CDK2CDK9 | |
| SCHEMBL31672441 | 0.69 | KDR (0.46) | KDRCCNT1CCNE1CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311825-A1 | Pyrimidineamines as angiogenesis modulators | GlaxoSmithKline LLC (US) | 2011-04-20 | — | — | EP | claimed |
| US-7858626-B2 | Pyrimidineamines as angiogenesis modulators | GLAXOSMITHKLINE LLC (US) | 2010-12-28 | — | — | US | claimed |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-11-22 | — | — | US | claimed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | claimed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
| EP-1343782-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | claimed |
| WO-2002059110-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | claimed |
| EP-3789027-A1 | BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-20120277258-A1 | Chemical Compounds | LEO OSPREY LIMITED (JE) | 2012-11-01 | — | — | US | disclosed |
| US-8114885-B2 | Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer | GLAXOSMITHKLINE LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-11-22 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-7105530-B2 | inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
| EP-1343782-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002059110-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | TYMS, TYMP, DPYD | KDR 5/4885GPR68 1131/4885CCNT1 548/4885 |
| US-20070015756-A1 | Chemical compounds | KDR, FLT4, FLT1 | KDR 1/4885GPR68 1293/4885CCNT1 236/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | KDR 648/4885GPR68 1328/4885CCNT1 1835/4885 |
| US-20120277258-A1 | Chemical Compounds | KDR, FLT4, FLT1 | KDR 1/4885GPR68 1293/4885CCNT1 236/4885 |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | KDR 1/4885GPR68 1293/4885CCNT1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.